[[Amphotericin B]], [[posaconazole]], and aggressive surgical resection are the hallmarks of [[mucormycosis]] treatment. While amphotericin is typically administered intravenously, less is known about the use of intrathecal amphotericin B
((Grannan BL, Yanamadala V, Venteicher AS, Walcott BP, Barr JC. Use of external 
ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic
abscess. J Clin Neurosci. 2014 May 19. pii: S0967-5868(14)00167-2. doi:
10.1016/j.jocn.2014.01.008. [Epub ahead of print] PubMed PMID: 24852901.)).

----
[[Cladophialophora bantiana]] tends to be resistant to [[amphotericin B]]. Accordingly, Al-Abdely et al. evaluated amphotericin B and three triazoles--posaconazole, itraconazole, and fluconazole--for treatment of C. bantiana infection in mice. In immunosuppressed ICR mice infected intravenously, posaconazole, itraconazole, and amphotericin B prolonged survival. This improvement in survival corresponded with a reduction in brain fungal concentrations for mice which were given itraconazole and posaconazole, but not amphotericin B. In nonimmunosuppressed BALB/c mice infected intracerebrally, posaconazole showed dose-dependent responses in survival and reduction of brain tissue counts. These responses were observed for short, delayed, and prolonged therapy. Although [[posaconazole]] prolonged the survival of mice with reductions in brain fungal counts, it did not sterilize brain tissue with continuous therapy for 8 weeks. They concluded that posaconazole shows promise for the treatment of C. bantiana brain infections
((Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR. Antifungal therapy of
experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana.
Antimicrob Agents Chemother. 2005 May;49(5):1701-7. PubMed PMID: 15855484; PubMed
Central PMCID: PMC1087650.
)).